en بیماری های دهان Oral Medicine پژوهشي Research <p> <strong>Objectives</strong> To investigate the role of PET-derived imaging markers in predicting metastatic nasopharyngeal carcinoma (NPC) outcomes. <strong></strong></p><p> <strong>Materials and methods</strong> A total of 56 patients with metastatic NPC were enrolled. Before treatment, all of the participants underwent 18F-FDG PET/CT. The following 18F-FDG PET parameters were assessed: standardised uptake value, metabolic tumour volume (MTV), and total lesion glycolysis. Multivariate Cox proportional hazards models were used to identify the independent predictors of survival. </p><p> <strong>Results</strong> The multivariate analysis showed that performance status>1 (P=0.007), Epstein–Barr virus (EBV) DNA titre>5000copies/mL (P=0.001), and MTV>110mL (P=0.013) were independent risk factors for progression-free survival (PFS). Male sex (P=0.004), performance status>1 (P<0.0001), EBV DNA level>5000copies/mL (P<0.0001), and MTV>110mL (P=0.003) independently predicted overall survival (OS). The 2-year PFS and OS rates of the patients with MTV⩽110mL were 23.2% and 43%, respectively, compared with 0% and 9.1%, respectively, for those with MTV>110mL. Combining the MTV with the EBV DNA titre allowed further survival stratification by dividing the patients into three groups with distinct PFS (2-year rates=30.8%, 7.1%, and 0%, P<0.0001) and OS (2-year rates=68.4%, 40%, and 0%, P<0.0001) rates. </p><p> <strong>Conclusion</strong> The MTV appears to be an independent risk factor in metastatic NPC patients. This factor is complementary to the EBV DNA titre for predicting survival in metastatic NPC. </p><hr><p></p><p> <strong>Source: </strong>Journal of Oral Oncology </p><p> <a href="http://www.oraloncology.com/article/S1368-8375(12)00244-8/abstract" target="_blank"><font color="#0033ff">Full Text</font></a> </p> Metabolic tumour volume, Total lesion glycolysis, Standardised uptake value, Metastasis, Nasopharyngeal carcinoma, 18F-FDG PET/CT, Epstein–Barr virus, Prognosis, Head and neck cancer 0 0 http://idai.ir/browse.php?a_code=A-10-32-859&slc_lang=en&sid=1 Sheng-Chieh Chan 10031947532846003750 10031947532846003750 Yes Department of Nuclear Medicine, Chang Gung Memorial Hospital, Keelong, Taiwan Cheng-Lung Hsu 10031947532846003751 10031947532846003751 No Division of Haematology/Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan Tzu-Chen Yen 10031947532846003752 10031947532846003752 No Department of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan Shu-Hang Ng 10031947532846003753 10031947532846003753 No Department of Diagnostic Radiology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan Chun-Ta Liao 10031947532846003754 10031947532846003754 No Department of Otorhinolaryngology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan Hung-Ming Wang 10031947532846003755 10031947532846003755 No Division of Haematology/Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan